Pharma

Taking stock of the drug industry, from the lab to the medicine chest

Hires
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: E.U. health chief calls Trump freeloading claim ‘fake news’; one drug maker says no to Right to Try

By Ed Silverman

Gottlieb Generic Drugs
Pharmalot

Frustrated at the pace of biosimilar development, FDA yanks a draft guidance

By Ed Silverman

Oxycodone script
Pharmalot

Canada looks to restrict how drug makers market opioids

By Ed Silverman

Pharmalot

Pharmalittle: A ‘right to try’ drug may cost $300,000; a rash of shortages for a new shingles vaccine

By Ed Silverman

Prescription Medication
Pharmalot

Consumer group petitions FDA to yank a widely prescribed gout drug over heart risks

By Ed Silverman

Pharmalot
Pharmalot

European Parliament restricts antibiotic use in food-producing livestock

By Ed Silverman

Vitamin pills
Pharma

Number of drug makers lobbying Congress on pricing issues skyrockets

By Lev Facher

Pharmalot

Pharmalittle: A campaign downplays concerns over antibiotics given animals; U.K. parents step up fight over Vertex drug

By Ed Silverman

FDA Campus
Pharmalot

FDA says drug shortages fell last year, but don’t blame the agency for persistent problems

By Ed Silverman

Lamar Alexander 340B
Politics

Key lawmaker calls for more scrutiny of hospitals using drug discount program — but no broader changes

By Erin Mershon

In the Lab

Archived chat: last week in CRISPR — cancer, patents, and a dip in the market

By Sharon Begley

Pharmalot

Pharmalittle: Valeant suffers a setback; CVS will use the Postal Service to deliver meds to your door

By Ed Silverman

Pharmalot

Pharmalittle: Chinese companies poaching big pharma talent; a battle over generic Suboxone looms

By Ed Silverman

Kaleo Naloxone Donation 02
Exclusive

Donations of $4,500 overdose antidote were PR gold for drug maker — but some kits were close to expiring

By Max Blau

Oxycodone
Pharmalot

Investor coalitions finding success pushing drug makers on pricing and opioid distribution

By Ed Silverman

Pharmalot
Pharmalot

‘Right-to-try’ law may have been unnecessary with previous success of FDA program, study argues

By Ed Silverman

Hires
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: Bristol cancer drug is approved in China; Teva gets a headache over migraine trial flops

By Ed Silverman

Prison
Pharmalot

Can a federal drug discount program unlock savings for state prisons?

By Ed Silverman

Chuck Grassley CREATES
Politics

Bill to encourage generic-drug development passes a key hurdle

By Erin Mershon

Pharmalot

Pharmalittle: Feds fight bid to disclose opioid shipments; Allergan moves to appease critics

By Ed Silverman

Hydrocodone
Pharmalot

The DEA is playing ‘whack-a-mole’ as it tries to stamp out the opioid crisis

By Ed Silverman

NEJM Dengue Vaccine
Pharma

Sanofi’s new dengue challenge: find a diagnostic that will make its vaccine safe to use

By Helen Branswell

FDA Rare Disease
Pharmalot

A bill would preserve the status quo of a contentious drug discount program for hospitals

By Ed Silverman

Pharmalot

Pharmalittle: Celgene issues a mea culpa; Azar remains adamant that Medicare should not negotiate prices

By Ed Silverman

Prescription benefit managers
Politics

FDA broadens guidelines on what information drug makers can share with insurers

By Ike Swetlitz

FDA campus
Pharmalot

The trouble with those post-marketing studies required by the FDA

By Ed Silverman

Politics

NIH spells out $500 million plan to improve addiction treatment and pain management

By Lev Facher

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy